First-in-class solution consolidates multiple assays into a single test, enabling broader viral detection, faster time-to-result and more confident decision-making in regulated biopharmaceutical ...

OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on its EpiSwitch 3D genomics ...

New adventitious viral agent (AVA) detection test offers rapid, sensitive, and affordable viral screening for biomanufacturers OXFORD, England & VIENNA, Austria, August 07, 2025--(BUSINESS ...

First-in-class solution consolidates multiple assays into a single test, enabling broader viral detection, faster time-to-result and more confident decision-making in regulated biopharmaceutical ...

EpiSwitch PSE boosts the predictive accuracy of current standard PSA test from 55%, to 94% for determining the presence or absence of prostate cancer CPT PLA Code 0433U has been issued to Oxford ...